Pharmacogenomics research grant awarded to Wilma Kiander

News • 28.11.2017

Doctoral student M.Sc (Pharm.) Wilma Kiander was selected to be the recipient of the € 15,000 research grant provided by DRA Consulting Oy.

The subject of Wilma Kiander’s research is the impact of genotype on the efficacy and safety of hypercholesterolemia therapies: the effect of rare OATP1B1 transporter protein variants on the pharmacokinetics of rosuvastatin. She is performing her doctoral studies under the guidance of Heidi Kidron and Mikko Niemi at the Division of Pharmaceutical Biosciences, a part of the Faculty of Pharmacy at the University of Helsinki.

The research project will considerably contribute to the knowledge on the research of rarer variants, interindividual variability in drug response, and the clinical significance of these particular genotypes to statin therapy.

The methods developed in the course of this study can also be utilised in risk analysis as well as selection of study subjects for clinical studies during the development of novel pharmaceutical substances, which will diminish the expensive risk of failure in drug development process.

The grant was allocated for utilisation of pharmacogenomics in drug therapies, and the impact of the research on public health and society was emphasized in the selection process.

The recipient of the DRA 15th anniversary grant was announced today at the educational event on genomic information and individualized drug therapy organized by Pharmaceutical Information Centre.